Stock Market Reviews

INBX (Inhibrx Biosciences, Inc.) News

Get the latest news, insights, and market updates on INBX (Inhibrx Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Inhibrx Reports Third Quarter 2025 Financial Results
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.
  Nov 14, 2025 - $INBX
• LGND: Target Up On Improved Growth Outlook
  By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third quarter, with revenues almost double our estimates and adjusted core earnings per share (EPS) more than 60% greater. While contributions from the spin out of Pelthos contributed the most, revenue growth in other areas was also strong.
  Nov 10, 2025 - $INBX
• Inhibrx Announces Participation in Upcoming Scientific Conferences
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:
  Nov 4, 2025 - $INBX
• Evaluating Inhibrx Biosciences (INBX) Valuation Following Breakthrough Phase 2 Results for Ozekibart
  Inhibrx Biosciences (INBX) drew considerable attention after announcing that its lead candidate, ozekibart, delivered a clear progression-free survival benefit in advanced or metastatic chondrosarcoma during its latest Phase 2 study. This result is especially relevant because ozekibart is now the first investigational therapy to achieve such an outcome in this rare cancer. Patients previously had no systemic treatment options. Interim data in colorectal cancer and Ewing sarcoma further fueled...
  Oct 26, 2025 - $INBX
• Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
  If ozekibart secures FDA clearance, it would become the first targeted therapy approved for chondrosarcoma.
  Oct 24, 2025 - $INBX
• Inhibrx shares surge after bone cancer drug slows disease progression in trial
  (Reuters) -Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in
  Oct 23, 2025 - $INBX
• Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company also provided updates on the ongoing expansion cohorts investigating ozekibar
  Oct 23, 2025 - $INBX
• Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosar
  Oct 22, 2025 - $INBX
• Owning 45% shares,institutional owners seem interested in Inhibrx Biosciences, Inc. (NASDAQ:INBX),
  Key Insights Institutions' substantial holdings in Inhibrx Biosciences implies that they have significant influence...
  Oct 11, 2025 - $INBX
• Insiders See US$5.42m Investment In Inhibrx Biosciences Jump Last Week
  NasdaqGS:INBX 1 Year Share Price vs Fair Value Explore Inhibrx Biosciences's Fair Values from the Community and select...
  Aug 15, 2025 - $INBX